All In Biotech

Drug Trial Radar · NCT06722430

A Study to Assess Change in How Oral Icalcaprant With Itraconazole Moves Through the Body in Healthy Adult Participants

A Phase 1 Open-label Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics of Icalcaprant in Healthy Adult Subjects

Last checked: Nov 19, 2026Latest source record: Jan 28, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

12

Actual

Start

Nov 13, 2024

Primary completion

Jan 13, 2025

Study completion Jan 13, 2025

Sponsor

Lead sponsor
AbbVieAbbVie (ABBV)
Sponsor type
Industry
First posted
Dec 9, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Basic science
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study is to assess the change of itraconazole, a strong CYP3A inhibitor, on the pharmacokinetics, safety, and tolerability of a single dose of icalcaprant in healthy participants.

Conditions

  • Healthy Volunteer

Interventions

  • IcalcaprantDrug

    Oral capsule

  • Itraconazole (ITZ)Drug

    Oral capsule

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum Observed Plasma Concentration (Cmax) of IcalcaprantTime frame: Up to approximately 14 days
  2. Time to Cmax (Tmax) of IcalcaprantTime frame: Up to approximately 14 days
  3. Terminal Phase Elimination Rate Constant (Beta) of IcalcaprantTime frame: Up to approximately 14 days
  4. Terminal Phase Elimination Half-Life (t1/2) of IcalcaprantTime frame: Up to approximately 14 days
  5. Area under the plasma concentration-time curve (AUC) of IcalcaprantTime frame: Up to approximately 14 days
  6. Area under the plasma concentration-time curve from time 0 until the last measurable Concentration (AUCt) of IcalcaprantTime frame: Up to approximately 14 days
  7. Area under the plasma concentration-time curve from time 0 to infinity (AUCinf) of IcalcaprantTime frame: Up to approximately 14 days
  8. Number of Participants with Adverse Events (AEs)Time frame: Up to approximately 47 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Acpru /Id# 271617

    Grayslake, Illinois

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.